DuoResp Spiromax® in the daily therapy of asthma and COPD. A non-interventional study of satisfaction, preference and user friendliness as well as of the clinical efficacy profile.

TEVA GmbH0 个研究点目标入组 4,036 人开始时间: 2014年7月30日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1) Adult male or female patients (= 18 years) with confirmed diagnosis of asthma bronchiale or COPD
•2) Patients with indication of a regular intake of a combination of inhalative corticosteroids and long-acting ß2 adrenergic receptor agonists
•3) Patients who are currently receiving or a switched to DuoResp Spiromax®
•4) Written informed consent

•1) Diseases which are contraindicated according to the summary of product characteristics
•2) Parallel participation in an interventional clinical trial or participation within the last 4 weeks
•3) Upon investigator assessment patient suffers from diseases or there are other conditions which could have a negative impact on the course of the observation
•4) Patients with medical history of substance abuse (drugs, alcohol) or with other factors (e.g. serious psychiatric disease) which limit the patient's capacity to take part in the study activities
•5) Insufficient German language skills to understand the consent process and to complete the questionnaires correctly
•6) Patients who were or are involved in the planning and execution of the study (applicable for Teva employees and study site staff)
•7) Patient is not able to give his/her consent

发起方